Boston Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements to address blood sugar management and inflammatory diseases. It produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy post-meal blood glucose levels. The company’s lead product candidates include BTI-320, a non-systemic, carbohydrate based compound, which has completed a Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic patients; and IPOXYN, an injectable anti-necrosis drug candidate ...
1750 Elm Street
Manchester, NH 03104
Founded in 2009
Boston Therapeutics, Inc. announced delayed 10-Q filing
Nov 16 15
On 11/16/2015, Boston Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Boston Therapeutics, Inc. Announces Executive Changes
Sep 4 15
On September 1, 2015, the Chief Financial Officer of Boston Therapeutics, Inc., Tony Squeglia, submitted his letter of resignation as an officer and employee of the company for health reasons. Until a successor is appointed, the company's Chief Executive Officer, David Platt, will serve as Chief Financial Officer.
Boston Therapeutics, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 13 15
Boston Therapeutics, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $38,851 compared to revenue of $21,391 a year ago. The increase is primarily related to larger shipments to Advance Pharmaceutical as compared to the three months ended June 30, 2014. Net loss was $686,238 or $0.02 per basic and diluted share, against $1,211,095 or $0.03 per basic and diluted share a year ago. Operating loss was $511,237 compared to $1,206,107 a year ago.
For the six months, the company reported revenue of $90,180 compared to revenue of $65,218 a year ago. Net loss was $1,362,525 or $0.04 per basic and diluted share, against $2,778,239 or $0.07 per basic and diluted share a year ago. Operating loss was $1,246,110 compared to $2,764,237 a year ago.